Eagerly awaited data with the anti-PD-L1 x 4-1BB bispecific acasunlimab raise liver toxicity concerns.

The latest first-in-human entrants include an anti-TROP2 ADC from Jiangsu Hansoh and a mystery bispecific from Johnson & Johnson.